Focus Stocks
Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference
Published on Tuesday, 07 February 2012 14:10 Written by TradersHuddle Staff
NATICK, Mass., Feb. 7, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink Swann 2012 Global Healthcare Conference on February 15 in New York.
Hank Kucheman, Chief Executive Officer, Mike Mahoney, President, and Jeff Capello, Executive Vice President and Chief Financial Officer, will participate in a 30-minute question and answer session regarding the Company beginning at approximately 11:00 a.m. ET.
A live webcast of the question and answer session will be available to all interested parties via Boston Scientific's website. Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors. Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.
This webcast is being hosted by Leerink Swann. The replay will be archived and available at www.bostonscientific.com/investors beginning approximately one hour following the completion of the question and answer session.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
|
CONTACT: |
Denise Kaigler |
|
|
508-650-8330 (office) |
|
|
Media Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
|
|
|
|
|
Eric Olson |
|
|
336-293-4393 (office) |
|
|
Media Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
|
|
|
|
|
Sean Findlen |
|
|
617-520-7268 (office) |
|
|
Media Relations |
|
|
Weber Shandwick |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
|
|
|
|
|
Sean Wirtjes |
|
|
508-652-5305 (office) |
|
|
Investor Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
SOURCE Boston Scientific Corporation
Related Articles
- Trading Idea: Entry Levels for Boston Scientific
- Bears Appeared on Boston Scientific
- Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
- PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
- One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
- Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
- Boston Scientific Announces Schedule For EuroPCR 2012
- Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia
- Boston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions
Related Partner Headlines
- Boston Scientific: PROMUS Element Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study - Benzinga
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent - Benzinga
- Boston Scientific Announces Positive Data from Lotus Transcatheter Aortic Valve Trial - Benzinga
- Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial - Benzinga
- UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific - Benzinga
- Boston Scientific Announces Schedule For EuroPCR 2012 - Benzinga
- Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia - Benzinga
- Boston Scientific Renews Agreement with Lumenis to Deliver Innovative Laser Products to Treat Urologic Conditions - Benzinga
- Boston Scientific Announces Launch of PROMUS Element Platinum Chromium Stent System in Japan - Benzinga
- Boston Scientific Announces First Implants of TELIGEN Implantable Defibrillator in China - Benzinga
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com -
Market Preview: Low-Grade Uncertainty - TheStreet.com -
The EPA's Dangerous Game - TheStreet.com -
Sticking with the Preferred Plan - TheStreet.com -
Infoblox Posts Blowout Earnings; Shares Rise - TheStreet.com -
Salesforce.com Inc. (CRM): Today's Featured Computer Software & Services Loser - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012 -
Diamond Value Management strategy and corporate turnaround leverages Rockwell repositioning -
Verizon Singapore Lauded for Its Sustainability Efforts -
Photo Release -- Cars For a Living: The World's First High-Octane Business Podcast -
Internal Fixation Systems, Inc. Enters Into $7.5M Equity Purchase Agreement With Hyde Park Advisors, LLC, an Affiliate of Institutional Investor Central Park Financial -
Sims Metal Management Market Update for Fiscal 2012 -
Block & Leviton LLP reminds investors that deadline to seek a lead plaintiff position in Swisher Hygiene Inc. is May 29, 2012; informs of expanded Class Period









